Drug Profile
RGH 2716
Alternative Names: TDN 345Latest Information Update: 11 Oct 2000
Price :
$50
*
At a glance
- Originator Takeda
- Developer Gedeon Richter
- Class Anti-ischaemics; Neuroprotectants; Nootropics
- Mechanism of Action Calcium channel antagonists; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral ischaemia; Cognition disorders
Most Recent Events
- 11 Oct 2000 Discontinued-Preclinical for Cerebral ischaemia in Hungary (Unknown route)
- 11 Oct 2000 Discontinued-Preclinical for Cognition disorders in Hungary (Unknown route)
- 12 Jun 2000 Profile reviewed but no significant changes made